SCHEMBL20767572

SCHEMBL20767572

COC(C)COc1nc2c(ccn2COCC[Si](C)(C)C)cc1Br

nearest known ligand 0.35

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21751870 0.87 DGAT1 (0.34) DGAT1
SCHEMBL28440805 0.86 DGAT1 (0.33) DGAT1
SCHEMBL25349464 0.84 DGAT1 (0.38) DGAT1
SCHEMBL21751562 0.84 DGAT1 (0.38) DGAT1
SCHEMBL26195129 0.83 DGAT1 (0.34) DGAT1
Ammonia Solution, Strong SCHEMBL28939497 0.83 DGAT1 (0.38) DGAT1
SCHEMBL25886857 0.83 DGAT1 (0.38) DGAT1
SCHEMBL21751919 0.82 DGAT1 (0.34) DGAT1
SCHEMBL23165244 0.82 DGAT1 (0.37) DGAT1
SCHEMBL21751778 0.82 DGAT1 (0.37) DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3672975-A1 CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES Newave Pharmaceutical Inc. (US) 2020-07-01 — — EP disclosed
WO-2020041406-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC. (US) 2020-02-27 — — WO disclosed
WO-2019040550-A1 CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES NEWAVE PHARMACEUTICAL INC. (US) 2019-02-28 — — WO disclosed
Send feedback